Junchao Xu

Nov 21, 2024 | nature.com | Xuexiang Han |Mohamad-Gabriel Alameh |Rakan El-Mayta |Kelsey Swingle |Junchao Xu |Ningqiang Gong | +5 more

AbstractIonizable lipids largely determine the biocompatibility of lipid nanoparticles (LNPs) and the efficacy for mRNA delivery. Rational design and combinatorial synthesis have led to the development of potent and biodegradable ionizable lipids, yet methodologies for the stepwise optimization of ionizable lipid structure are lacking.

Oct 1, 2024 | nature.com | Lulu Xue |Gan Zhao |Ningqiang Gong |Xuexiang Han |Zebin Xiao |Junchao Xu | +11 more

AbstractSystemic delivery of messenger RNA (mRNA) for tissue-specific targeting using lipid nanoparticles (LNPs) holds great therapeutic potential. Nevertheless, how the structural characteristics of ionizable lipids (lipidoids) impact their capability to target cells and organs remains unclear.

Jul 9, 2024 | nature.com | Xuexiang Han |Ningqiang Gong |Lulu Xue |Majed Ghattas |Junchao Xu |Gan Zhao | +8 more

AbstractLipid nanoparticles (LNPs) are widely used for mRNA delivery, with cationic lipids greatly affecting biodistribution, cellular uptake, endosomal escape and transfection efficiency. However, the laborious synthesis of cationic lipids limits the discovery of efficacious candidates and slows down scale-up manufacturing.

Jun 7, 2024 | nature.com | Junchao Xu |Guangjun Nie

Correction to: Signal Transduction and Targeted Therapy https://doi.org/10.1038/s41392-024-01794-4, published online 15 April 2024After the article was published online,1 the authors noticed one inadvertent mistake in Supplementary Fig. S19. The image of lung H&E in the Lip-Dox group was repeatedly inserted as the image of Dox group by mistake during the preparation of the figures. The correct figure was provided as follows.

Apr 14, 2024 | nature.com | Junchao Xu |Guangjun Nie

AbstractThe inadequate tumor accumulation of anti-cancer agents is a major shortcoming of current therapeutic drugs and remains an even more significant concern in the clinical prospects for nanomedicines. Various strategies aiming at regulating the intratumoral permeability of therapeutic drugs have been explored in preclinical studies, with a primary focus on vascular regulation and stromal reduction. However, these methods may trigger or facilitate tumor metastasis as a tradeoff.